Browse studies
Find your next paid study
4 recruiting studies matching your filters
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
Background: People with neurofibromatosis 1 (NF1) who have plexiform neurofibromas (pNFs) can have pain that affects their daily lives. This study aims to imp…
Neurofibromatosis 1Plexiform Neurofibromas
Estimated
~$10 – $675
National Cancer Institute (NCI)NCT02544022
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibro…
NeurofibromasMPNST
Estimated
~$10 – $750
M.D. Anderson Cancer CenterNCT07298083
Phase 1
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
This study is designed to establish the foundation for a new therapy for neurofibromatosis Type I (NF1)-related cutaneous neurofibromas (cNFs) by assessing the…
NF1NeurofibromatosisCutaneous Neurofibroma+3 more
Estimated
~$10 – $6,250
Johns Hopkins UniversityNCT07102394
Phase 1
A Phase 1/1b Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PAS-004, a MAPK/ERK Kinase 1/2 (MEK 1/2) Inhibitor, in Adult Participants With Neurofibromatosis Type 1 (NF1) With Symptomatic and Inoperable, Incompletely Resected, or Recurrent Plexiform Neurofibromas
The main purpose of this clinical trial is to test PAS-004 in people with at least one symptomatic plexiform neurofibroma due to Neurofibromatosis Type 1 (NF1)…
NF1 MutationNeurofibroma PlexiformNeurofibroma, Plexiform+2 more
Estimated
~$10 – $8,750
Pasithea Therapeutics Corp.NCT06961565